shortagewatch

Home / Companies / Bayer

Company family · HQ DE

Bayer: medicine shortages

BAYN · Xetra

As of 2 Nov 2026, 68 Bayer products have a reported shortage across 12 countries, covering 17 medicines.

Products short68rank #29 of 464
Medicines17active ingredients
Countries12/16
New in 90 days35+16 vs market pace
Typical duration2 monthsmedian so far
Manufacturing52%demand-driven 23%

Where

Canada2Germany1Italy7Spain7Ireland3Austria3Belgium7Switzerland4Czechia8Norway6Sweden13Japan7

Which therapeutic classes

Blood19Various16Cardiovascular system11Sensory organs5Dermatologicals4Cancer and immune system4Anti-infectives3Genito-urinary system and sex hormones2Nervous system1

Why, compared with all companies

Manufacturing problemIncreased demandActive ingredient shortageDistribution or logisticsCommercial decision or withdrawalRegulatory or licensingOtherNot stated
BayerBayer: Manufacturing problem 23 (35%)35%Bayer: Increased demand 10 (15%)15%Bayer: Distribution or logistics 2 (3%)Bayer: Commercial decision or withdrawal 3 (5%)5%Bayer: Other 3 (5%)5%Bayer: Not stated 24 (37%)37%All companiesAll companies: Manufacturing problem 4,893 (36%)36%All companies: Increased demand 1,873 (14%)14%All companies: Active ingredient shortage 367 (3%)All companies: Distribution or logistics 336 (2%)All companies: Commercial decision or withdrawal 435 (3%)All companies: Regulatory or licensing 131 (1%)All companies: Other 1,244 (9%)9%All companies: Not stated 4,221 (31%)31%

Manufacturing problems point to the company's own supply chain; increased demand often follows a competitor's shortage or a demand shock.

When its current shortages began

05101520Dec: 0Jan ’25: 0Feb: 0FebMar: 0Apr: 0May: 1MayJun: 0Jul: 0Aug: 0AugSep: 0Oct: 0Nov: 0NovDec: 0Jan ’26: 2Feb: 6FebMar: 0Apr: 3May: 0MayJun: 1Jul: 9Aug: 4AugSep: 12Oct: 15Nov: 4Nov

Long-run trend in Canada

Canada dashboard
051015202017: 520172018: 1520182019: 1320192020: 420202021: 620212022: 1620222023: 1520232024: 2020242025: 720252026: 82026

Canada publishes every report since 2017, so it shows whether this company is reporting more or fewer shortages over time. The current year is partial.

Against its peers

Viatris995Teva903Sandoz599Pfizer491Accord (Intas)484Stada349Zentiva340Fresenius Kabi339Apotex326Sun Pharma250Aurobindo226Towa (Pensa)201Krka187Sanofi158Bayer68

Breadth vs depth

1101001,00010,0001101001,000Products short (log scale)Medicines affected (log scale)Viatris: 995 / 248ViatrisTeva: 903 / 289TevaSandoz: 599 / 198SandozPfizer: 491 / 122PfizerAccord (Intas): 484 / 151Accord (Intas)Stada: 349 / 140Zentiva: 340 / 159ZentivaFresenius Kabi: 339 / 81Apotex: 326 / 152Sun Pharma: 250 / 77Aurobindo: 226 / 111Towa (Pensa): 201 / 102Krka: 187 / 67Sanofi: 158 / 45Jamp: 151 / 74Baxter: 149 / 27Sawai: 148 / 68Hikma: 126 / 44Glenmark: 105 / 39Sanis: 98 / 54Cheplapharm: 86 / 28GSK: 85 / 38Advanz (Amdipharm): 81 / 24Nichi-Iko: 77 / 29Takeda: 76 / 10Johnson & Johnson: 75 / 19Neuraxpharm: 75 / 19Novartis: 70 / 32Biomed: 64 / 21Daiichi Sankyo: 59 / 18Orifarm: 59 / 40Medochemie: 56 / 14Pharmascience: 51 / 32Marcan: 51 / 16Doc Generici: 50 / 25B. Braun: 49 / 17AA Pharma: 46 / 26H E: 46 / 15Octapharma: 42 / 6Jv E: 42 / 1Kyowa Pharmaceutical: 42 / 16Novo Nordisk: 41 / 8Odan: 41 / 31Aspen: 41 / 13Sterop: 41 / 16Nipro: 41 / 17Dr. Reddy's: 40 / 24Organon: 40 / 20Laboratoire Riva: 40 / 23Kern Pharma: 40 / 30Bausch Health: 39 / 30Bracco: 38 / 6G.L.: 38 / 13Tatsumi Kagaku: 38 / 24Otsuka: 37 / 4Eli Lilly: 37 / 12Piramal Critical: 35 / 13Imuna Pharm: 35 / 4AbbVie: 34 / 15Medical Valley: 34 / 8Orion: 34 / 24Rowex: 34 / 19Takata Pharmaceutical: 33 / 17Aristo: 32 / 16Norgine: 32 / 3Gedeon Richter: 31 / 11Eql: 31 / 9Guerbet: 30 / 5Lukas Heil-Betriebsst: 30 / 0Roche: 29 / 14Omega: 29 / 18Bgp: 29 / 18Holsten -: 29 / 3Menarini: 29 / 17Paladin: 28 / 17Grifols: 28 / 9Ge: 28 / 6Merck & Co. (MSD): 27 / 14Ferring: 27 / 7Bayer: 68 / 17Bayer

Further right: more products short. Higher: more different medicines affected.

Medicines short

MedicineWhere this company is shortProductsEarliest startMain reasonShort anywhere
Rivaroxaban1710 Apr 2026Manufacturing problem13/16
Diatrizoic Acid717 Feb 2026Not stated5/16
Riociguat722 Jul 2026Manufacturing problem4/16
Gadobutrol623 Jul 2026Manufacturing problem5/16
Sorafenib431 Jul 2026Not stated6/16
Aflibercept325 Sep 2026Commercial decision or withdrawal2/16
Ciprofloxacin323 Oct 2026Not stated9/16
Gadoxetic Acid326 Jun 2026Manufacturing problem3/16
Vericiguat330 Sep 2026Manufacturing problem3/16
Bifonazole221 Apr 2026Not stated3/16
Ciprofloxacin230 Jan 2026Manufacturing problem1/16
Clotrimazole226 Oct 2026Increased demand3/16
Coagulation Factor VIII227 Jul 2026Not stated6/16
Acetylsalicylic Acid, Combinations excl. Psycholeptics130 May 2025Distribution or logistics3/16
Drospirenone and Estrogen122 Oct 2026Increased demand2/16
Estradiol118 Sep 2026Increased demand11/16
Nifedipine19 Nov 2026Increased demand6/16

Shortage data describes supply, not company finances. A shortage can mean lost sales for the supplier or extra demand for its competitors. Nothing here is investment advice; tickers are for identification only and may be out of date.